A previous study demonstrated a precision treatment strategy for EZH2-aberrant tumors that was based on tumor-intrinsic MLL1 expression and concurrent inhibition of epigenetic crosstalk and feedback MAPK activation69. The gene discussed is KMT2A; the disease is neoplasm.